Post-baseline data

These omissions will not cause bias only under some circumstances. In particular, subjects in each of the treatment groups should receive equal scrutiny for protocol violations and all such violators should be excluded, in relation to the first point. For the second and third points, the fact that patients do not take study medication or do not provide any post-baseline data should be unrelated to the treatments to which such subjects were assigned. Any potential bias arising from these exclusions should be fully investigated. 

The purpose of using change-from-baseline analysis data sets is to measure what effect some therapeutic intervention had on some kind of diagnostic measure. A measure is taken before and after therapy, and a difference and sometimes a percentage difference are calculated for each post-baseline measure. These data sets are generally normalized... 

The considerations so far in this chapter have been on the evaluation of efficacy. For safety we usually define the safety set as the set of subjects who receive at least one dose of study medication. Usually the safety set will coincide with the full analysis set, but not always. There may well be a patient who started on medication, but withdrew immediately because of a side effect. This patient is unlikely to have provided post baseline efficacy data and so could be excluded from the full analysis set. 

Results from these studies are expressed as the extent of cortisol suppression, evaluated by the quotient of 8 00 a.m. post-DEX cortisol to 8 00 a.m. basehne cortisol. Expressing the data in this manner accounts for individual differences in baseline cortisol levels and allows for a more precise characterization of the strength of negative feedback inhibition as a continuous rather than as a dichotomous variable. Whereas studies of major depression empha-... 

The result is shown in Figure 16.8. From these results, one can directly obtain the enthalpy of the transition. The procedure, like that for the analysis of the optical data, requires the estimation of a pre- and post-transitional baseline. For relatively short temperature intervals, the baselines are often assumed to be linear and are extrapolated to the mid-temperature as shown in Figure 16.8. The area under the curve in Figure 16.8 is the enthalpy of the transition. That is,... 

Before actual data can be fit to a model, extraneous effects manifested in the trace must be removed, such as the shift in baseline as a result of the change in heat capacity of the sample during the transformation (see section 3.7.2). It may, for some device designs (e.g. post-type DTA), be difficult to purify the instrument output to represent only the latent heat from the transformation because of random baseline float. Hence, the data set fitting a particular model is a necessary but insufficient criterion for guaranteeing that the model describes the measured phenomenon. 

The signal quality (= low detector noise) and sample rate should be sufficiently high to obtain correct results, otherwise post processing of the data is necessary, such as smoothing, baseline correction, etc. Even then the result of the integration in Eq. 6.126 depends very much on the extension of the baseline, and the obtained value of the second moment can be very inaccurate (Chapter 2.7, Section 6.5.3.3). 

In a study using beagle dogs dermally exposed to 0.4 mg of radioactive MBOCA/cm, no measurable radioactivity was detected in blood or plasma up to 24 hours later (Manis et al. 1984). The highest concentration of radioactivity 24 hours post-exposure was found in the bile. No unmetabolized MBOCA was present in the bile. Detectable concentrations of radioactivity were found in the liver, kidney, fat, and lung. Urinary excretion of unmetabolized MBOCA was a small but consistent fraction, 0.4-0.5%, of the total urinary radioactivity, and the authors concluded that this may be a useful index of acute exposure. These results support the hypothesis that dermal absorption is a viable entry for MBOCA. They also demonstrate that the circulatory system distributes MBOCA to the liver, kidneys, fat, and lungs. In this study, intravenously exposed animals were used as controls in order to obtain a 100% absorbed dose baseline for comparison with the pharmacokinetic data obtained for dermal exposure. 

---